Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Canagliflozin | Tirzepatide | |
|---|---|---|
| Category | Pharmaceuticals | Pharmaceuticals |
| Standard Dose | — | — |
| Timing | — | — |
| Cycle Duration | — | — |
| Evidence Level | Moderate (longevity), Strong (cardiorenal) | Strong (FDA-approved) |
SGLT2 inhibitor originally developed for type 2 diabetes. Blocks glucose reabsorption in kidneys, creating a mild glucose deficit that activates AMPK and mimics caloric restriction. Extended lifespan in male mice in the ITP.
Dual GIP/GLP-1 receptor agonist. Enhances insulin secretion, reduces glucagon, slows gastric emptying, and acts on hypothalamic appetite centers. Produces greater weight loss than semaglutide in head-to-head trials. Also improves cardiovascular risk markers.
Fast buy links (we may earn a small commission at no extra cost).
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →